Ivabradine

Area of Science:

• Cardiology
• Pharmacology

Background:

• Chronic heart failure (CHF) with reduced ejection fraction remains a significant clinical challenge.
• Current therapies aim to manage symptoms and improve outcomes, but further interventions are needed.

Purpose of the Study:

• To evaluate the efficacy and safety of Ivabradine, a selective If inhibitor, in patients with stable CHF.
• To assess Ivabradine's impact on cardiovascular mortality and heart failure hospitalizations.

Main Methods:

• The Systolic Heart Failure Treatment with the If inhibitor Trial (SHIFT) was a large-scale, randomized, placebo-controlled clinical trial.
• Participants had stable CHF, reduced ejection fraction, were in sinus rhythm, and on background therapy including beta-blockers.

Main Results:

• Ivabradine significantly reduced the primary composite endpoint (cardiovascular death or heart failure hospitalization) by 18%.
• A 26% reduction in heart failure hospitalizations was observed, with greater benefits in patients with heart rate ≥75 bpm.
• Improvements in quality of life and reverse remodeling were noted, with good overall safety, primarily marked by increased bradycardia and visual disturbances.

Conclusions:

• Ivabradine is a valuable therapeutic option for specific CHF patients, reducing hospitalizations and mortality.
• Its efficacy and tolerability were consistent across various subgroups, including those with diabetes, low blood pressure, renal dysfunction, or COPD.
• Ivabradine is indicated for CHF with systolic dysfunction in patients with heart rate ≥75 bpm, alongside standard therapy or when beta-blockers are contraindicated/not tolerated.